Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease
Open accessAbstract
BACKGROUND: Although the FibroTest has been validated as a biomarker to determine the stage of fibrosis in non-alcoholic fatty liver disease (NAFLD) with results similar to those in chronic hepatitis C (CHC), B (CHB), and alcoholic liver disease (ALD), it has not yet been confirmed for the prediction of liver-related death. AIM: To validate the 10-year prognostic value of FibroTest in NAFLD for the prediction of liver-related death. METHOD: Patients in the prospective FibroFrance cohort who underwent a FibroTest between 1997 and 2012 were pre-included. Mortality status was obtained from physicians, hospitals or the national register. Survival analyses were based on univariate (Kaplan-Meier, log rank, AUROC) and multivariate Cox risk ratio taking into account age, sex and response to anti-viral treatment as covariates. The comparator was the performance of the FibroTest in CHC, the most validated population. RESULTS: 7082 patients were included; 1079, 3449, 2051, and 503 with NAFLD, CHC, CHB, and ALD, respectively. Median (range) follow-up was 6.0 years (0.1-19.3). Ten year survival (95% CI) without liver-related death in patients with NAFLD was 0.956 (0.940-0.971; 38 events) and 0.832 (0.818-0.847; 226 events; P = 0.004) in CHC. The prognostic value (AUROC / Cox risk ratio) of FibroTest in patients with NAFLD was 0.941 (0.905-0.978)/1638 (342-7839) and even higher than in patients with CHC 0.875 (0.849-0.901; P = 0.01)/2657 (993-6586). CONCLUSIONS: The FibroTest has a high prognostic value in NAFLD for the prediction of liver-related death. (ClinicalTrials.gov number, NCT01927133).
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Several observational studies showed that LSM had good accuracy for liver-related events, liver-related and overall mortality.
“Several observational studies showed that LSM had good accuracy for liver-related events, liver-related and overall mortality. 178,183,184”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [183]
The Results (FibroTest prognostic performance; page not provided) report good accuracy for transient elastography, a liver stiffness measurement method, in predicting liver-related deaths in a NAFLD subgroup (AUROC 0.923). The paper does not establish its accuracy for other liver-related events or overall mortality; its main prognostic analyses concern FibroTest. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836 · see citing works
Marrero, J. A., Kulik, L., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018) · Hepatology · doi:10.1002/hep.29913 · Cited by 4,549 · see citing works
Imbert‐Bismut, F., Ratziu, V., Piéroni, L., Charlotte, F., Benhamou, Y., & Poynard, T. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04258-6 · Cited by 1,422 · see citing works
Marrero, J. A., Kulik, L., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., Heimbach, J. K., et al. (2019) · Clinical Liver Disease · doi:10.1002/cld.802 · Cited by 646 · see citing works
Boursier, J., Vergniol, J., Guillet, A., Hiriart, J.-B., Lannes, A., Le Bail, B., Michalak, S., Chermak, F., Bertrais, S., Foucher, J., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.023 · Cited by 400 · see citing works
Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection
Chou, R., & Wasson, N. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-11-201306040-00005 · Cited by 369 · see citing works
Thiele, M. S., Madsen, B. S., Hansen, J. F., Detlefsen, S., Antonsen, S., & Krag, A. A. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.01.005 · Cited by 272 · see citing works
Mechanisms of Disease: proatherogenic HDL—an evolving field
Navab, M., Anantharamaiah, G. M., Reddy, S. T., Lenten, B. J. V., Ansell, B. J., & Fogelman, A. M. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0245 · Cited by 246 · see citing works
Poynard, T., Lassailly, G., Diaz, E., Clément, K., Caiazzo, R. J., Tordjman, J., Munteanu, M., Perazzo, H., Demol, B., Callafe, R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030325 · Cited by 146 · see citing works
Correction of HDL Dysfunction in Individuals With Diabetes and the Haptoglobin 2-2 Genotype
Asleh, R., Blum, S., Kalet-Litman, S., Alshiek, J. A., Miller‐Lotan, R., Asaf, R., Rock, W., Aviram, M., Milman, U., Shapira, C., et al. (2008) · Diabetes · doi:10.2337/db08-0450 · Cited by 139 · see citing works
Katzke, V. A., Sookthai, D., Johnson, T., Kuhn, T. E., & Kaaks, R. (2017) · BMC Medicine · doi:10.1186/s12916-017-0976-4 · Cited by 119 · see citing works
Serum Lipid Profiles and Cancer Risk in the Context of Obesity: Four Meta-Analyses
Melvin, J. C., Holmberg, L., Rohrmann, S., Loda, M. F., & Hemelrijck, M. V. (2013) · Journal of Cancer Epidemiology · doi:10.1155/2013/823849 · Cited by 95 · see citing works
Munteanu, M., TINIAKOS, D. G., Anstee, Q. M., Charlotte, F., Marchesini, G., Bugianesi, E., Trauner, M. A., Romero‐Gómez, M., de Oliveira, C. P. M. S., Day, C. P., et al. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13770 · Cited by 95 · see citing works
Houot, M., Ngo, Y., Munteanu, M., Marque, S., & Poynard, T. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13446 · Cited by 94 · see citing works
Poynard, T., Munteanu, M., Deckmyn, O., Ngo, Y., Drane, F., Messous, D., Castille, J. M., Housset, C., Ratziu, V., & Imbert‐Bismut, F. (2011) · BMC Gastroenterology · doi:10.1186/1471-230x-11-39 · Cited by 73 · see citing works
Xu, X., Kong, H., Song, R., Zhai, Y., Wu, X., Ai, W., & Liu, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100182 · Cited by 56 · see citing works
Borlak, J. T., Chatterji, B., Londhe, K. B., & Watkins, P. B. (2013) · Genome Medicine · doi:10.1186/gm493 · Cited by 35 · see citing works
Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia
Perazzo, H., Munteanu, M., Ngo, Y., Lebray, P., Seurat, N., Rutka, F., Couteau, M., Jacqueminet, S., Giral, P., Monneret, D., et al. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12946 · Cited by 31 · see citing works
Poynard, T., Peta, V., Munteanu, M., Charlotte, F., Ngo, Y., Ngo, A., Perazzo, H., Deckmyn, O., Pais, R., Mathurin, P., et al. (2018) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001304 · Cited by 25 · see citing works
Poynard, T., Munteanu, M., Charlotte, F., Perazzo, H., Ngo, Y., Deckmyn, O., Pais, R., Merrouche, W., de Lédinghen, V., Mathurin, P., et al. (2018) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001064 · Cited by 24 · see citing works
Naveau, S., Essoh, B. M., Ghinoiu, M., Marthey, L., Njiké‐Nakseu, M., Balian, A., Lachgar, M., Prevot, S., & Perlemuter, G. (2014) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000041 · Cited by 16 · see citing works
Peta, V., Tsé, C., Perazzo, H., Munteanu, M., Ngo, Y., Ngo, A., Ramanujam, N., Verglas, L., Mallet, M., Ratziu, V., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189436 · Cited by 16 · see citing works
Flagged first, then by citations
1 of the 23 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210 · see citing works
Berzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925 · see citing works
Ginès, P., Krag, A., Abraldes, J. G., Solà, E., Fabrellas, N., & Kamath, P. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01374-x · Cited by 1,663 · see citing works
(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 510 · see citing works
Lee, J., Vali, Y., Boursier, J., Spijker, R., Anstee, Q. M., Bossuyt, P. M., & Zafarmand, M. H. (2020) · Liver International · doi:10.1111/liv.14669 · Cited by 385 · see citing works
Advances in non-invasive assessment of hepatic fibrosis
Loomba, R. S., & Adams, L. A. (2020) · Gut · doi:10.1136/gutjnl-2018-317593 · Cited by 351 · see citing works
Boursier, J., Hagström, H., Ekstedt, M., Moreau, C., Bonacci, M., Cure, S., Ampuero, J., Nasr, P., Tallab, L., Canivet, C. M., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.031 · Cited by 206 · see citing works
Petta, S., Sebastiani, G., Viganò, M., Ampuero, J., Wai-Sun Wong, V., Boursier, J., Berzigotti, A., Bugianesi, E., Fracanzani, A. L., Cammà, C., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.06.045 · Cited by 197 · see citing works
Noninvasive assessment of liver fibrosis in NAFLD
Sanyal, A. J., Castera, L., & Wong, V. W.-S. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.03.042 · Cited by 157 · see citing works
Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers
Agbim, U. A., & Asrani, S. K. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1579641 · Cited by 126 · see citing works
Noninvasive Assessment of Liver Fibrosis
Castéra, L., Rinella, M. E., & Tsochatzis, E. A. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2403308 · Cited by 115 · see citing works
Noninvasive tests for liver fibrosis in 2024: are there different scales for different diseases?
Lai, J. C., Liang, L. Y., & Wong, G. L. (2023) · Gastroenterology report · doi:10.1093/gastro/goae024 · Cited by 50 · see citing works
Johnston, M. P., Patel, J. A., & Byrne, C. D. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200128094231 · Cited by 49 · see citing works
Screening strategy for non-alcoholic fatty liver disease
Zhang, S., Mak, L., Yuen, M., & Seto, W. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0336 · Cited by 44 · see citing works
Serum biomarkers for liver fibrosis
Chen, Z., Ma, Y., Cai, J., Sun, M., Zeng, L., Wu, F., Zhang, Y., & Hu, M. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.09.022 · Cited by 40 · see citing works
Marchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.04.028 · Cited by 35 · see citing works
Marchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.04.029 · Cited by 33 · see citing works
Wang, Y., Song, S. J., Jiang, Y., Lai, J. C., Wong, G. L., Wong, V. W., & Yip, T. C. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0246 · Cited by 32 · see citing works
Top-Down Proteomics Identifies Plasma Proteoform Signatures of Liver Cirrhosis Progression
Forte, E., Sanders, J. M., Pla, I., Kanchustambham, V. L., Hollas, M. A. R., Huang, C.-F., Sanchez, A., Peterson, K. N., Melani, R. D., Huang, A., et al. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100876 · Cited by 22 · see citing works
Associazione Italiana per lo Studio del Fegato (AISF), S. I. D. D. (. A. S. I. D. (. (2021) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-021-01287-1 · Cited by 22 · see citing works
Deckmyn, O., Poynard, T., Bédossa, P., Paradis, V., Peta, V., Pais, R., Ratziu, V., Thabut, D., Brzustowski, A., Gautier, J., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10030699 · Cited by 20 · see citing works
Large Scale MRI Collection and Segmentation of Cirrhotic Liver
Jha, D., Susladkar, O., Gorade, V., Keleş, E., Antalek, M. D., Seyithanoğlu, D., Cebeci, T., Aktas, H. E., Kartal, G. D., Kaymakoğlu, S., et al. (2025) · Scientific Data · doi:10.1038/s41597-025-05201-7 · Cited by 17 · see citing works
Noninvasive diagnosis in alcohol‐related liver disease
Hadefi, A., Degré, D., Trépo, E., & Moreno, C. (2020) · Health Science Reports · doi:10.1002/hsr2.146 · Cited by 12 · see citing works
Poynard, T., Peta, V., Deckmyn, O., Pais, R., Ngo, Y., Charlotte, F., Ngo, A., Munteanu, M., Imbert‐Bismut, F., Monneret, D., et al. (2019) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001606 · Cited by 12 · see citing works
Peta, V., Zhu, J., Lubman, D. M., Huguet, S., Imbert‐Bismut, F., Bolbach, G., Clodic, G., Mathéron, L., Ngo, Y., Pais, R., et al. (2020) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2019.12.010 · Cited by 10 · see citing works
Serum biomarkers for liver fibrosis assessment
Maroto‐García, J., Álvarez, A. M., de Pedro, M. P. S., Soto, A. B., & González, Á. (2023) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2023-0081 · Cited by 9 · see citing works
The diagnostic conundrum in non-alcoholic fatty liver disease
Rosato, V., Masarone, M., Aglitti, A., & Persico, M. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00018 · Cited by 9 · see citing works
Xiao, L., Zeng, L., Wang, J., Hong, C., Zhang, Z., Wu, C., Cui, H., Li, Y., Li, R., Liang, S., et al. (2025) · Advanced Science · doi:10.1002/advs.202410527 · Cited by 7 · see citing works
Chen, F., Yao, Y., Li, Z., Deng, L., & He, R. (2023) · Scientific Reports · doi:10.1038/s41598-023-39977-8 · Cited by 7 · see citing works
Wang, L. Y., & Wang, Y. (2026) · International Journal of General Medicine · doi:10.2147/ijgm.s593387 · Cited by 5 · see citing works
Yongpisarn, T., Thimphitthaya, C., Laoveeravat, P., Wongjarupong, N., & Chaiteerakij, R. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i8.949 · Cited by 4 · see citing works
Izha, А., Dragomiretska, N., Gushcha, S., Sierpińska, L. E., & PLAKIDA, A. L. (2023) · Annals of Agricultural and Environmental Medicine · doi:10.26444/aaem/160323 · Cited by 4 · see citing works
Luo, Y., Yue, W., Li, Z., & Wang, P. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-67 · Cited by 4 · see citing works
Novel Prognostic Indicators to reflect the grade of liver fibrosis in hepatic patients
El-Gazar, M. M. A., Fahmi, A. E., mohamed, A., & Elhakim, H. A. (2021) · Egyptian Journal of Chemistry · doi:10.21608/ejchem.2021.104682.4837 · Cited by 4 · see citing works
Penalized likelihood optimization for censored missing value imputation in proteomics
Etourneau, L., Fancello, L., Wieczorek, S., Varoquaux, N., & Bürger, T. (2024) · Biostatistics · doi:10.1093/biostatistics/kxaf006 · Cited by 4 · see citing works
Williams, D. M., Nagaraj, J., Stephens, J. W., & Min, T. (2025) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2025.21.1.4 · Cited by 3 · see citing works
Biomarcadores séricos para la evaluación de la fibrosis hepática
Maroto‐García, J., Moreno‐Álvarez, A., de Pedro, M. P. S., Soto, A. B., & González, Á. (2024) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2023-0172 · Cited by 2 · see citing works
Li, Y., Liu, X., Li, Q., Xu, X., Jiang, B., Wang, T., & Zhang, J. (2026) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2026.119798 · Cited by 2 · see citing works
Gavril, O. I., Gavril, R. S., Mitu, F., Gavrilescu, O., Popa, I. V., Tatarciuc, D., Drugescu, A., Oprescu, A. C., Gherasim, A., Mihalache, L., et al. (2023) · Metabolites · doi:10.3390/metabo13040571 · Cited by 2 · see citing works
Bush, A., & Torres, D. M. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15036 · Cited by 2 · see citing works
Brekhunets, R. M., Андреев, Д. Н., Maev, I. V., Dicheva, D. T., & Киримовна, К. А. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-225
- Authors
- Munteanu, M., Pais, R., Peta, V., Deckmyn, O., Moussalli, J., Ngo, Y., Rudler, M., Lebray, P., Charlotte, F., Thibault, V., Lucidarme, O., Ngo, A., Imbert‐Bismut, F., Housset, C., Thabut, D., Ratziu, V., Poynard, T., & the FibroFrance Group
- Affiliations
- Inserm (FR)
- BioPredictive Paris France
- Assistance Publique – Hôpitaux de Paris (FR)
- Hepatology Department Assistance Publique‐Hôpitaux de Paris Pitié‐Salpêtrière Hospital Paris France
- Corresponding author
- Poynard, Thierry
- ORCID
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2018-10-17
- Volume
- 48
- Issue
- 10
- Pages
- 1117-1127
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- PMC
- PMC6221139
- OpenAlex
- W2897602569
- Cited by
- 42
- References
- 23
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 6 · 2023: 6 · 2022: 4 · 2021: 8 · 2020: 7 · 2019: 2 · 2018: 2
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Alimentary Pharmacology & Therapeutics (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- FibroTest, non-alcoholic fatty liver disease, liver-related mortality, prognostic factors, liver fibrosis, chronic hepatitis C, chronic hepatitis B, alcoholic liver disease, survival analysis, liver disease staging, liver cirrhosis, liver cancer, liver failure
- MeSH terms
- Adult, Female, Follow-Up Studies, France, Humans, Liver Diseases, Alcoholic, Male, Middle Aged, Prognosis, Prospective Studies, Time Factors, Cohort Studies, Biomarkers, Survival Analysis, Hepatitis B, Chronic, Hepatitis C, Chronic, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
